Ohana Biosciences, Inc.

Ohana Biosciences, Inc.

was a biotechnology company based in Cambridge, Massachusetts, focused on reproductive health. Founded in 2016 by Flagship Pioneering, the company developed a pioneering sperm biology platform aimed at addressing male fertility challenges. Ohana's innovative approach included single-cell sequencing and computational biology to analyze sperm cells, leading to significant insights into sperm activation mechanisms. The company created several product candidates, including SPERTILITY, an ex vivo sperm cell treatment designed to enhance outcomes in in vitro fertilization (IVF) and intrauterine insemination (IUI). Ohana also worked on non-hormonal contraception options and therapeutics aimed at reducing pregnancy complications. The company served individuals and couples facing male factor infertility, as well as clinicians and researchers in reproductive medicine. Ohana Biosciences ceased operations on April 30, 2024.